Synaffix licenses ADC technology to BigHat Biosciences
Synaffix BV announces that it has licensed its ADC technology to BigHat Biosciences. BigHat will combine Synaffix technology with its world-class machine learning antibody design platform for the development of a new ADC pipeline programme.
Under the terms of the agreement, BigHat will receive target-specific access to Synaffix’s late clinical-stage, site-specific ADC technology platform, which enables the transformation of antibodies into proprietary, best-in-class ADC products. BigHat will also gain access to Lonza’s end-to-end ADC offering.
About Synaffix
Synaffix B.V. is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform based on GlycoConnect™, HydraSpace®, and toxSYN® technologies. Together, these technologies enable any company with an antibody to develop proprietary, best-in-class ADC products under a single licence from Synaffix.
The Synaffix ADC Platform Technology
Synaffix’s proprietary ADC technology platform consists of GlycoConnect™, GlycoConnect™ High DAR Technology, HydraSpace®, and toxSYN® technologies. These technologies aim to enable best-in-class ADCs from any antibody, with significantly enhanced efficacy and tolerability. The combination of these three technologies provides developers with a “one-stop” and easy-to-use ADC technology platform, allowing any antibody developer to create its own proprietary ADC and enabling any ADC developer to expand its pipeline further and increase its competitive position.
Read the full press release here.
Find more news here.